Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
Noopur Raje(Massachusetts General Hospital), G. David Roodman(Indiana University Health), Thierry Façon(Université de Lille), Evangelos Terpos(National and Kapodistrian University of Athens), Arun Balakumaran(Allogene Therapeutics (United States)), Wolfgang Willenbacher(Universität Innsbruck), Vânia Hungria(Faculdade de Ciências Médicas da Santa Casa de São Paulo), A. Keith Stewart(The University of Texas MD Anderson Cancer Center), Ada Braun(National Cancer Centre Japan), Yulia Alexeeva(City Clinical Hospital No 31), Andrew Spencer(The Alfred Hospital), A. Feng(Amgen (United States)), Saroj Vadhan‐Raj(The University of Texas MD Anderson Cancer Center)
Cited by 50
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k